HIV2 doses,2-6monthsapart≤q2y40-70 y.o.,ASCVD ≥10%, lowbleeding risk52y.o.≥20%diabetes≥ 200mg/dL≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors50y.o.insufficientevidenceforscreening≥5.7%tamoxifenaromataseinhibitorshormonetherapyraloxifeneHepatitisCPREVENTequationq15y≥ 126mg/dL65y.o.colorectalcancer40y.o.cervicalcancerq1yovariancancerq3yaspirincardiovasculardiseasehypertensionpneumococcal≥ 140mg/dLGailmodel40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor75y.o.60y.o.≥ 100mg/dLlungcancerTimedup andgo testmultidoseinitial series,then 1 doseat 2-6months3%q1-2ymammogrambased on lifeexpectancy /health status40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorq5yanxiety≥6.5%womenage 55-64 y.o.q2ydementiatobaccouseFractureRiskAssessmentTooloverweight/ obesitycommunity-dwelling,postmenopausalwomen40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsherpeszosterstatin< 60y.o.HepatitisBTyrer-Cuzickmodel40-59 y.o.,ASCVD ≥10%, lowbleeding riskq1ymammogramdepressionbreastcancerdyslipidemia1 dose; 2doses (2-6monthsapart) ifimmunocompHIV2 doses,2-6monthsapart≤q2y40-70 y.o.,ASCVD ≥10%, lowbleeding risk52y.o.≥20%diabetes≥ 200mg/dL≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors50y.o.insufficientevidenceforscreening≥5.7%tamoxifenaromataseinhibitorshormonetherapyraloxifeneHepatitisCPREVENTequationq15y≥ 126mg/dL65y.o.colorectalcancer40y.o.cervicalcancerq1yovariancancerq3yaspirincardiovasculardiseasehypertensionpneumococcal≥ 140mg/dLGailmodel40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor75y.o.60y.o.≥ 100mg/dLlungcancerTimedup andgo testmultidoseinitial series,then 1 doseat 2-6months3%q1-2ymammogrambased on lifeexpectancy /health status40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorq5yanxiety≥6.5%womenage 55-64 y.o.q2ydementiatobaccouseFractureRiskAssessmentTooloverweight/ obesitycommunity-dwelling,postmenopausalwomen40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsherpeszosterstatin< 60y.o.HepatitisBTyrer-Cuzickmodel40-59 y.o.,ASCVD ≥10%, lowbleeding riskq1ymammogramdepressionbreastcancerdyslipidemia1 dose; 2doses (2-6monthsapart) ifimmunocomp

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. HIV
  2. 2 doses, 2-6 months apart
  3. ≤ q2y
  4. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  5. 52 y.o.
  6. ≥ 20%
  7. diabetes
  8. ≥ 200 mg/dL
  9. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  10. 50 y.o.
  11. insufficient evidence for screening
  12. ≥ 5.7%
  13. tamoxifen
  14. aromatase inhibitors
  15. hormone therapy
  16. raloxifene
  17. Hepatitis C
  18. PREVENT equation
  19. q15y
  20. ≥ 126 mg/dL
  21. 65 y.o.
  22. colorectal cancer
  23. 40 y.o.
  24. cervical cancer
  25. q1y
  26. ovarian cancer
  27. q3y
  28. aspirin
  29. cardiovascular disease
  30. hypertension
  31. pneumococcal
  32. ≥ 140 mg/dL
  33. Gail model
  34. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  35. 75 y.o.
  36. 60 y.o.
  37. ≥ 100 mg/dL
  38. lung cancer
  39. Timed up and go test
  40. multidose initial series, then 1 dose at 2-6 months
  41. 3%
  42. q1-2y mammogram based on life expectancy / health status
  43. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  44. q5y
  45. anxiety
  46. ≥ 6.5%
  47. women age 55-64 y.o.
  48. q2y
  49. dementia
  50. tobacco use
  51. Fracture Risk Assessment Tool
  52. overweight / obesity
  53. community-dwelling, postmenopausal women
  54. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  55. herpes zoster
  56. statin
  57. < 60 y.o.
  58. Hepatitis B
  59. Tyrer-Cuzick model
  60. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  61. q1y mammogram
  62. depression
  63. breast cancer
  64. dyslipidemia
  65. 1 dose; 2 doses (2-6 months apart) if immunocomp